Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Merck Serono
- 08 Sep 2017 Primary endpoint has been met. (Progression-free survival rate (Assessed at 6 and 12 months.)) as per results published in the Annals of Oncology
- 08 Sep 2017 Results (data cut off: 30 Jun 2017) published in the Annals of Oncology
- 08 Sep 2017 Status changed to active, no longer recruiting.